The prospective dataset will initially be collected from patients participating in clinical trials initiated by us in multiple hospitals. Yamicc has now developed the ‘ReDiReCCT-GB trial’ within Erasmus MC and has recently started. In this clinical study, in principle, every new patient with a glioblastoma will participate and be followed from diagnosis. Each patient’s tumor will be fully genetically mapped, and it will be examined whether a drug is available based on the genetic profile.
We will also investigate whether promising drugs can actually reach the tumor cells, and we will use a new biological model to investigate whether a pre-test on the patient’s tumor tissue can prescribe the most effective drug. In this process, existing drugs that have proven effective against other forms of cancer will be tested on a large scale (called drug repurposing). This approach is an important ingredient in cost-effectively achieving improved and personalized treatments.